Pyrido[2,1-a]isoquinolin-5-ium | 231-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Pyrido[2,1-a]isoquinolin-5-ium
• 英文别名: benzo[a]quinolizin-5-ium
• CAS: 231-02-7
• 化学式: C13H10N+
• 分子量: 180.22
• InChiKey: XYIUTVDOILVALE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  4.1
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2933990090

文献信息

• Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Yang V. Bingwei

  公开号：US20060154962A1

  公开（公告）日：2006-07-13

  The invention relates to a class of novel non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein Z, R, R 4 , R 5 , R a , R b , R c , and R d , are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  该发明涉及一类新型非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，并具有如下结构的化学式(I)或其立体异构体、前药、溶剂合物或药用可接受盐，其中Z、R、R4、R5、Ra、Rb、Rc和Rd在此处定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• [EN] HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS HETEROCYCLIQUES DU RECEPTEUR GLUCOCORTICOIDE AP-1, ET/OU ACTIVITE NF-20050811US5569655ADORITY JR JOHN A [US], et al19961029AASee references of EP 1711488A4
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005073221A1

  公开（公告）日：2005-08-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of Formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein A, B, J, K, Z, R, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一种新型的非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，并具有如下结构的化学式（I）或其立体异构体、前药、溶剂合物或其药用可接受的盐，其中A、B、J、K、Z、R、Ra、Rb、Rc和Rd在此有所定义。还提供了包含该化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• Benzoquinolizinium salt derivatives as anticancer agents
  申请人：Lombardi Paolo

  公开号：US20110015222A1

  公开（公告）日：2011-01-20

  13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): processes for the preparation of said compounds, pharmaceutical compositions containing said compounds and the use of said compounds for the manufacture of medicaments suitable for the treatment of cancerous diseases.

  13-取代的5,6-二氢二苯并[a,g]喹啉盐化合物的通式（I）：制备上述化合物的方法，含有上述化合物的药物组合物以及利用上述化合物制造适用于治疗癌症疾病的药物的用途。
• [EN] CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME<br/>[FR] COMPOSES ACTIVATEURS DU CANAL CFTR, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：WO1998005642A1

  公开（公告）日：1998-02-12

  (EN) CFTR channel activator compounds from the benzo[c]quinolizinium family or families of compounds derived therefrom, as well as pharmaceutical compositions containing said compounds, and the uses thereof, particularly for treating cystic fibrosis, are disclosed.(FR) La présente invention a pour objet des composés activateurs du canal CFTR, appartenant à la famille des benzo[c]quinoliziniums, ou à des familles de composés dérivées de cette dernière, ainsi que les compositions pharmaceutiques contenant ces composés, et leurs utilisations, notamment dans le cadre du traitement de la mucoviscidose.

  (中)本发明涉及来自苯并[c]喹啉族或其衍生物族的CFTR通道激活剂化合物，以及含有该化合物的药物组合物和其用途，特别是用于治疗囊性纤维化。
• Compositions and methods for treating disorders associated with salt or fluid retention
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2671584A2

  公开（公告）日：2013-12-11

  Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.

  本文描述了降低患者发生与体液和/或盐潴留有关的疾病的风险或治疗这种疾病的方法。这些方法包括向患者施用选自以下几种的制剂：a) 减少肠道钠吸收的制剂；b) 增加肠道阴离子分泌的制剂；或 c) 既减少肠道钠吸收又增加肠道阴离子分泌的制剂。